Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90 Therasphere Therapy with Quantitative Nuclear Imaging
Protocol Number:
J1289
Phase:
NULL
Physician:
Jean Geschwind
Purpose:
This research is being conducted to determine the best way to estimate tumor and liver treatment doses in patients with hepatocellular carcinoma (HCC) treated with TheraSphere. The study focuses on the comparison of imaging before and after the TheraSphere procedure, rather than the procedure itself.
Eligibility:
Patients with HCC recommended for radioembolization.
Treatment:
Patients with HCC recommended for radioembolization receive TheraSphere therapy, and immediately after, a PET/CT scan (positron emission tomography combined with a CT scan) and SPECT (single photon emission computer tomography) of the liver are performed. The two images are compared to measure the dose that was absorbed by the tumor(s) and the dose absorbed by the non-tumor areas of the liver. Participants will be on study for 1 day consisting of the 24 hours after the procedure and then followed for 30 days.
Population:
Adult
Last Update
10/01/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer